T1	Participants 266 342	patients with large or locally advanced HER2-positive (HER2+) breast cancers
T2	Participants 768 967	core biopsy samples from 27 HER2+ breast cancer patients enrolled in a preoperative clinical trial using trastuzumab, nab-paclitaxel and carboplatin combination therapy (BrUOG BR-211B (NCT00617942)).
T3	Participants 1264 1286	18Â weeks of treatment
